Loading...
XNASTFFP
Market cap288kUSD
Dec 12, Last price  
0.07USD
Name

TFF Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:TFFP chart
P/E
P/S
0.39
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
19.42%
Rev. gr., 5y
%
Revenues
734k
0000000733,871
Net income
-21m
-370,370-178,605-3,842,186-11,752,899-18,440,818-30,987,4800-21,243,231
CFO
-16m
L-41.34%
-359,393-187,749-2,126,988-11,216,122-16,615,589-29,556,971-27,342,160-16,038,195
Earnings
Mar 26, 2025

Profile

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
IPO date
Oct 25, 2019
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
734
 
Cost of revenue
22,629
32,681
31,986
Unusual Expense (Income)
NOPBT
(21,895)
(32,681)
(31,986)
NOPBT Margin
Operating Taxes
(51)
Tax Rate
NOPAT
(21,895)
(32,681)
(31,935)
Net income
(21,243)
 
(30,987)
68.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,125
405
28,885
BB yield
-40.73%
-32.13%
-328.00%
Debt
Debt current
167
81
Long-term debt
147
301
Deferred revenue
Other long-term liabilities
417
Net debt
(5,164)
(16,231)
(33,795)
Cash flow
Cash from operating activities
(16,038)
(27,342)
(29,557)
CAPEX
(95)
(1,551)
(869)
Cash from investing activities
(95)
(1,551)
(869)
Cash from financing activities
5,013
11,751
28,885
FCF
(19,377)
(32,376)
(34,838)
Balance
Cash
5,478
16,612
33,795
Long term investments
Excess cash
5,441
16,612
33,795
Stockholders' equity
(118,477)
(97,192)
(65,342)
Invested Capital
127,758
120,262
104,079
ROIC
ROCE
EV
Common stock shares outstanding
1,793
1,199
993
Price
7.02
568.57%
1.05
-88.16%
8.87
-38.06%
Market cap
12,584
899.38%
1,259
-85.70%
8,806
-24.73%
EV
7,420
(14,972)
(24,988)
EBITDA
(21,392)
(32,293)
(31,875)
EV/EBITDA
0.46
0.78
Interest
Interest/NOPBT